Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Marken Expands Kit-Building Operations in Singapore

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
Singapore joins Marken’s other facilities around the globe.

Marken has announced that they have expanded their kit-building operations into Singapore due to a growing demand from its clients. The facility is fully operational and began shipping for its first client earlier this year.

The kit-building unit in Singapore is managed by a dedicated trained staff and is supported by the GMP operators and QA personnel who operate the depot facility.

The depot / kit facility is also adjacent to Marken’s Singapore distribution hub, located near the Chiangi airport. Marken staff can therefore receive drug product and kit materials at the depot, assemble and store kits, store drug product and distribute all clinical materials to investigator sites throughout Asia.

The addition of the Singapore site is part of an ongoing global expansion plan within Marken. With kit-building locations already operational in Hamburg, and now Singapore, Marken is also evaluating an additional kit-building facility in either Miami or Brazil in the coming months.

Marken currently produces 15,000 kits per month and distributes more than 350,000 kits annually to investigator sites around the world. Ample capacity is currently available, and more capacity will be added as client demand develops.

Wes Wheeler, Marken’s Chief Executive Officer, said, “We are pleased to be able to offer this expanded service to our clients in the APAC region. Our ability to assemble kits in Singapore gives us a solid platform in Asia and again enhances our portfolio of services to clients in the region. We look forward to serving more global clients with our other facilities as we continue to grow, both in the Asia region and around the world.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Marken Announces Completion of New Moscow Depot
New location will serve a growing number of new clinical trials in Russia.
Tuesday, December 15, 2015
Marken Offers Exclusive GPS Technology for Shipments
The advanced tracking device delivers real time monitoring for a variety of conditions.
Thursday, August 20, 2015
Marken Opens New Philadelphia Hub
Distribution of clinical trial supplies within all temperature ranges.
Saturday, May 16, 2015
Marken Announces Moscow Depot
Marken’s global depot network expands to seven.
Thursday, October 03, 2013
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!